 The presence of two forms of the enzyme complicate the design of potential drugs because one could compensate for the inhibition of the other.Also there the TIGR data base shows that there are 14 species of bacteria with the two forms of shikimate dehydrogenase.This is a problem for drug makers because there are two enzymes that a potential drug would need to inhibit at the same time.